The world's #1 fungal allergen — and the leading mold trigger for life-threatening asthma attacks.
Alternaria is one of the most abundant fungal genera in the outdoor environment. It is primarily a saprotrophic and plant pathogenic mold — colonizing dead and decaying plant material, soil, and living plant tissue as a pathogen of hundreds of crop species worldwide. It is also the most clinically significant allergenic mold genus, with its primary allergen protein, Alt a 1, recognized by the World Allergy Organization as the most sensitizing single mold allergen in existence.
Unlike the classic "water damage molds" such as Stachybotrys and Chaetomium, Alternaria is primarily an outdoor organism that enters buildings continuously. It does not require catastrophic water damage to establish indoor colonies — it needs only surfaces with persistent moderate moisture, such as window condensation, shower grout, or damp soil in houseplants. This characteristic makes it uniquely difficult to control: addressing an indoor Alternaria problem requires both source removal and reduction of the continuous outdoor spore load entering the building.
Alternaria alternata is identified by the World Allergy Organization as the most clinically important allergenic mold globally. In some geographic regions, 70–80% of patients with allergic asthma show IgE sensitization to Alternaria allergens.
The genus Alternaria contains approximately 300 species, but a single species — Alternaria alternata — dominates both outdoor air counts and indoor clinical significance. It is so prevalent that in most air quality reports, "Alternaria" without further species qualification implicitly refers to A. alternata. The species complex is cosmopolitan, found on every continent and in virtually every inhabited region, though its outdoor concentrations peak in hot, dry, and windy conditions that favor spore dispersal.
On surfaces, Alternaria colonies appear as dark olive-brown to greenish-black velvety or powdery growths. On culture media, colonies are initially white, rapidly turning dark gray to black with a fluffy or velvety texture as sporulation develops. The reverse side of the colony is typically dark brown to black.
The definitive identifying feature of Alternaria under microscopy is its large, multicellular conidia (spores). These are:
This combination of large size, distinctive muriform septation, and chain arrangement is unique to Alternaria and allows definitive identification by a trained mycologist on air or surface samples. No other common indoor mold shares this morphology.
Alternaria is commonly confused with Cladosporium because both grow in similar locations (window sills, bathroom grout) and appear dark greenish-black. Under microscopy they are completely different: Cladosporium has lemon-shaped to cylindrical spores arranged in branching chains, while Alternaria has large, muriform (brick-wall patterned) club-shaped spores that are unmistakable to trained laboratory personnel.
Unlike molds that arise strictly from indoor moisture problems, Alternaria continuously enters buildings from the outdoor environment. Understanding the entry pathways is essential for effective prevention, particularly for homes occupied by sensitized asthma patients.
Alternaria alternata is the most important allergenic mold in the world. This status is based on the combination of its ubiquitous airborne presence, the potency and prevalence of its primary allergen Alt a 1, and its documented association with severe and life-threatening allergic disease.
Alt a 1 is a secreted protein of approximately 30–31 kDa that constitutes a major structural component of Alternaria spore wall material. It is released during spore germination and fragmentation. Alt a 1 has no known sequence homology to other characterized fungal allergens, making it unique to Alternaria. It is recognized by IgE antibodies in approximately 90% of patients sensitized to Alternaria — making it the dominant sensitization allergen and the primary target for diagnostic testing.
Additional Alternaria allergens include Alt a 3 (heat shock protein 70), Alt a 4 (disulfide isomerase), Alt a 6 (enolase — a pan-allergen shared with other fungi), Alt a 7, and Alt a 10. The multi-allergen profile means that even patients who develop tolerance to Alt a 1 may continue to react to other Alternaria proteins, complicating immunotherapy outcomes.
Alternaria sensitization (detectable allergen-specific IgE to Alt a 1 or whole Alternaria extract) is found in:
Sensitization to Alternaria alternata is associated with a 6-fold increase in the risk of near-fatal asthma attacks compared to asthmatic patients who are not sensitized to Alternaria, according to data from the European Community Respiratory Health Survey and subsequent independent studies.
The relationship between Alternaria sensitization and severe asthma is one of the most robustly documented associations in clinical mycology. Multiple independent study cohorts across different continents have confirmed that Alternaria-sensitized asthmatics experience:
The syndrome of Severe Asthma with Fungal Sensitization (SAFS) is a recognized clinical entity defined by the combination of difficult-to-treat asthma (requiring high-dose inhaled corticosteroids plus at least one additional controller medication) and IgE sensitization to one or more fungal allergens, most commonly Alternaria and Aspergillus. SAFS represents an underdiagnosed subset of severe asthma with a specific therapeutic opportunity: antifungal treatment.
Two randomized controlled trials have demonstrated that itraconazole therapy in SAFS patients results in statistically significant improvements in asthma control scores, quality of life, and exacerbation rates. The proposed mechanism is reduction of the fungal burden in the airway mucosa that sustains the inflammatory state driving SAFS. Voriconazole is used in itraconazole-intolerant patients. This represents an underrecognized treatment option that should be discussed with an allergist or pulmonologist in any patient with difficult asthma and positive Alternaria serology.
One of the most striking clinical manifestations of Alternaria's potency is the phenomenon of thunderstorm asthma — epidemics of acute asthma attacks that occur during or immediately after certain types of thunderstorms, particularly in late summer and early fall. Several mechanisms are implicated, including osmotic rupture of large pollen grains releasing sub-respirable allergenic starch granules, but Alternaria is consistently one of the fungal species identified at elevated airborne concentrations during these events.
During a thunderstorm, wind gusts disturb surface-level fungal growth (decaying grass, leaf litter) and vertically mix high-altitude spore concentrations to ground level simultaneously, producing transient spore count spikes of orders of magnitude above background levels. In several documented thunderstorm asthma outbreaks (Melbourne, Australia 2016; Birmingham, UK 2002), Alternaria spore counts during the event exceeded 80,000 spores/m³ — versus typical background levels of 200–1,000 spores/m³.
Beyond asthma, Alternaria sensitization contributes to a broader atopic disease spectrum. The same IgE-mediated mechanisms that drive asthma in sensitized individuals also affect other organ systems.
Alternaria sensitization is significantly more prevalent in patients with severe atopic dermatitis compared to mild-to-moderate disease. Mechanistically, Alt a 1-specific IgE binding on skin mast cells and dermal dendritic cells triggers type I hypersensitivity reactions that worsen eczematous inflammation. Clinical studies have shown that allergen avoidance — including indoor Alternaria source reduction — can reduce eczema severity scores in sensitized patients, providing a modifiable treatment target beyond topical corticosteroids.
Alternaria is a leading fungal cause of seasonal and perennial allergic rhinitis. Sensitized patients experience nasal congestion, rhinorrhea, sneezing, and post-nasal drip that correlates with outdoor Alternaria spore counts — peaking in late summer and fall in most temperate climates. In some patients with chronic rhinosinusitis, Alternaria colonizes sinus mucosa, contributing to eosinophilic fungal rhinosinusitis (a noninvasive form of sinus disease requiring combined antifungal and anti-inflammatory treatment).
Ocular exposure to airborne Alternaria spores in sensitized individuals triggers IgE-mediated mast cell degranulation in the conjunctiva, producing the classic picture of allergic conjunctivitis: itching, watering, and redness, typically occurring concurrently with rhinitis symptoms during peak outdoor spore seasons.
In patients with concurrent allergic rhinitis, asthma, and eczema — the "atopic march" — Alternaria sensitization is one of the most important fungal contributors. Testing for Alternaria-specific IgE should be standard in any comprehensive allergy workup for patients with multi-system atopic disease.
While primarily an outdoor mold, Alternaria readily colonizes indoor surfaces when moisture conditions allow. It has a relatively low minimum water activity requirement of approximately 0.85 Aw, meaning it can grow on surfaces that are persistently damp rather than actively wet — a key distinction from water-damage molds like Stachybotrys that require near-saturation.
In standard air quality reports and ERMI dust testing, Alternaria is listed as a distinct species — not grouped with other dark-spored molds as Aspergillus/Penicillium often are. Its spore morphology (large, muriform, club-shaped) is sufficiently distinctive that trained analysts can identify it by direct microscopy without culture.
Alternaria alternata is classified as an ERMI Group 2 mold — meaning it is considered a common background mold present in most buildings regardless of water damage history. This classification can be misleading for patients with Alternaria sensitization: even at "expected background" counts, ambient Alternaria concentrations may be clinically significant for highly sensitized individuals.
The ERMI framework was designed primarily as a water-damage investigation tool, not as an allergen exposure assessment tool. For Alternaria-sensitized asthma patients, absolute spore counts (both in air samples and settled dust by ERMI QPCR) and their relationship to clinical symptom timing are more diagnostically useful than the Group 1/Group 2 ERMI classification alone.
In clinical practice, Alternaria-sensitized asthma patients should track their symptom severity against regional outdoor Alternaria spore count data (available through many regional allergy networks and weather services). Patients who experience symptom worsening during low outdoor count periods likely have a significant indoor Alternaria colonization source driving their symptoms year-round.
Alternaria is primarily a warm-weather, dry-condition mold. Its outdoor spore season in temperate North America follows a predictable pattern that patients and their families can use to anticipate high-risk periods and plan protective measures.
Low Moderate High Peak
Peak outdoor counts occur when warm temperatures (25–30°C) coincide with low relative humidity and wind — conditions that desiccate surface organic matter and maximize dry spore release and dispersal. Hot, dry August and September weather in the central and southern United States produces the highest Alternaria spore counts. By contrast, rainy weather temporarily washes spores from the air, providing brief symptom relief for sensitized patients before counts rebound as drying conditions return.
In regions with mild winters (US Gulf Coast, Mediterranean climates, coastal California), Alternaria can maintain detectable outdoor concentrations year-round, removing the traditional winter reprieve that patients in colder climates experience. For these patients, year-round allergen avoidance measures and potentially year-round allergen immunotherapy maintenance are more important.
Effective management of indoor Alternaria requires a two-pronged approach: eliminating established indoor colonization sites and reducing the continuous outdoor spore load entering the building. Neither approach alone is sufficient for sensitized patients.
For patients with clinically significant Alternaria sensitization — particularly those with moderate-to-severe allergic rhinitis or asthma triggered by Alternaria — allergen immunotherapy (AIT) represents a disease-modifying treatment option that is distinct from symptom management medications.
Subcutaneous Alternaria immunotherapy (allergy shots) involves regular injections of gradually increasing doses of standardized Alternaria alternata extract administered by an allergist. The treatment aims to shift the immune response from IgE-mediated hypersensitivity toward a tolerogenic profile involving regulatory T cells and blocking IgG4 antibodies.
Published clinical evidence for Alternaria SCIT demonstrates reduction in rhinitis and conjunctivitis symptom scores, reduction in rescue medication use, and in asthma-predominant patients, improvement in asthma control. The treatment requires 3–5 years of maintenance injection therapy to achieve sustained post-treatment tolerance.
Sublingual Alternaria immunotherapy (allergen drops or tablets administered under the tongue) is an alternative to SCIT that can be self-administered at home after initial medical supervision. While SLIT for Alternaria is not yet FDA-approved in the United States (unlike grass and ragweed SLIT tablets), it is prescribed off-label using validated standardized extracts by allergists familiar with the evidence base. European clinical guidelines support its use for Alternaria-triggered rhinitis and asthma.
Combined allergen immunotherapy targeting both Alternaria and Aspergillus has shown particular benefit in patients with Severe Asthma with Fungal Sensitization (SAFS). In this patient group, immunotherapy combined with targeted antifungal therapy achieves better asthma control than either treatment alone.
Alternaria is frequently compared with other outdoor molds encountered in air sampling and ERMI reports. The table below highlights key differences relevant to both identification and clinical management.
| Characteristic | Alternaria alternata | Cladosporium spp. | Epicoccum nigrum | Helminthosporium spp. |
|---|---|---|---|---|
| Colony color | Dark olive-black to gray-black | Olive-green to black | Yellow-orange to dark brown | Dark brown to black |
| Spore morphology | Large, muriform, club-shaped chains | Lemon-shaped; branching chains | Round, thick-walled, multicellular | Boat-shaped; distoseptate |
| Spore size | 20–200 µm (very large) | 2–7 µm (small) | 15–25 µm (large) | 30–100 µm (large) |
| Primary habitat | Soil, decaying plants, crop pathogens | Decaying organic matter, living plants | Decaying plant material, seeds | Grass, grain, decaying vegetation |
| Peak outdoor season | Late summer–fall (Jul–Oct) | Spring–fall (Apr–Nov) | Late summer (Aug–Sep) | Summer–fall (Jun–Oct) |
| Allergen importance | Highest — WHO-recognized #1 mold allergen | High — Cla h 8 is clinically significant | Moderate — Epi n allergens described | Moderate |
| ERMI Group | Group 2 | Group 2 | Not included in ERMI panel | Not included in ERMI panel |
| Minimum moisture (Aw) | 0.85 Aw | 0.86 Aw | 0.86 Aw | 0.87 Aw |
| Clinical Condition | Sensitization Prevalence | Key Diagnostic Marker | Primary Treatment | Role of Mold Avoidance |
|---|---|---|---|---|
| Allergic rhinitis (seasonal) | 20–30% of atopic patients | Alt a 1 IgE >0.35 kUA/L | Antihistamines; intranasal steroids; AIT | High — reduces symptom burden |
| Allergic asthma | Up to 70–80% in high-exposure regions | Alt a 1 IgE; SPT >3mm wheal | ICS/LABA; allergen immunotherapy | Very high — prevents exacerbations |
| SAFS (severe asthma) | ~35% of severe asthma patients | Total IgE >1000 IU/mL + fungal IgE | Add antifungal therapy (itraconazole) | Very high — required for control |
| Atopic dermatitis (eczema) | Elevated in severe AD cases | Alt a 1 IgE; patch testing | Topical steroids/calcineurin inhibitors; AIT | Moderate — reduces flare frequency |
| Allergic conjunctivitis | Concurrent with rhinitis in >70% | Alt a 1 IgE + ocular symptoms | Antihistamine eye drops; AIT | Moderate |
| Hypersensitivity pneumonitis | Rare — very high occupational exposure | Precipitating IgG antibodies; BAL lymphocytosis | Antigen avoidance; corticosteroids | Critical — remove from exposure source |
For healthy adults with no atopic disease, Alternaria at typical indoor background concentrations poses minimal direct health risk. The significant risk group is individuals with allergic asthma, particularly those who are IgE-sensitized to Alt a 1. In these patients, Alternaria is the most important fungal trigger for severe and near-fatal asthma attacks. For immunocompromised patients, Alternaria rarely causes invasive infection (unlike Aspergillus) but has been documented as a cause of cutaneous and subcutaneous infection. Children with early-onset asthma in homes with detectable indoor Alternaria should be tested for sensitization.
On surfaces, Alternaria appears as dark greenish-black to brown-gray velvety or powdery patches. It is commonly confused with Cladosporium, which grows in identical locations and appears visually similar. Under microscopy, Alternaria is definitively identified by its characteristic large, club-shaped (obclavate) spores with both transverse and longitudinal septa, creating a distinctive "brick wall" pattern. This morphology is unique and unmistakable to trained mycologists. Visual identification without laboratory confirmation is not reliable.
The most common indoor locations are window sills and frames (condensation zones), shower and bathtub grout, basement walls and floors with elevated humidity, under sinks with plumbing leaks, HVAC evaporator coils and condensate pans, soil of indoor houseplants, and damp fabrics or upholstery in poorly ventilated spaces. Alternaria is an outdoor mold that continuously enters buildings through open windows, HVAC air intakes, and on shoes and clothing, then colonizes any indoor surface sustaining water activity above approximately 0.85 Aw.
Yes — HEPA air purifiers are highly effective at removing Alternaria spores from indoor air. True HEPA filters (H13 or H14 standard) capture 99.97% or more of particles at 0.3 µm diameter. Alternaria spores are large (20–200 µm) and therefore captured with near-100% efficiency on the first pass through a properly sized HEPA purifier. For maximum benefit, purifiers should be placed in bedrooms and primary living areas, sized for at least 4–5 air changes per hour for the room volume, and run continuously during high outdoor spore season. Pre-filter maintenance (monthly cleaning during peak season) extends HEPA filter life.
No. "Black mold" is a colloquial term most commonly associated with Stachybotrys chartarum, a completely different fungal genus. Alternaria appears dark olive-brown to black on surfaces, but it is not Stachybotrys. The two organisms differ in growth requirements (Stachybotrys requires chronic high moisture; Alternaria grows at moderate moisture), toxin profiles (Stachybotrys produces trichothecene mycotoxins; Alternaria does not typically produce significant mycotoxins at indoor concentration levels), and disease mechanisms (Stachybotrys concerns focus on mycotoxin exposure; Alternaria concerns focus on IgE-mediated allergy). Laboratory identification is always required to distinguish them reliably.
Preventing Alternaria on window sills requires addressing the underlying moisture source — condensation — not simply cleaning existing growth. Upgrading from single-pane to double-pane windows dramatically reduces condensation. Maintaining indoor relative humidity at 40–55% RH year-round (measured at the window surface in winter) prevents the moisture film on which Alternaria establishes. If upgrading windows is not feasible, applying a moisture-absorbing interior window film and ensuring good air circulation across window surfaces (avoiding heavy curtains that trap moisture) reduces condensation duration. Regular cleaning with 3% hydrogen peroxide spray on all window sill surfaces (monthly during humid seasons) prevents re-establishment after initial removal.